Eledon Pharmaceuticals, Inc. (ELDN) stock
ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.12−0.25 (-10.57%)
Close on Nov 13, 2026Market cap $171.87MP/E –Yield –
Eledon Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Eledon Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $70.68M, up 6.0% year over year. For fiscal 2025 it was $66.27M, up 27.5% from the year before. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $66.27M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.27M | +27.5% |
| FY2024 | Dec 31, 2024 | $51.96M | +71.4% |
| FY2023 | Dec 31, 2023 | $30.31M | +11.9% |
| FY2022 | Dec 31, 2022 | $27.08M | +14.1% |
| FY2021 | Dec 31, 2021 | $23.74M | +287.1% |
| FY2020 | Dec 31, 2020 | $6.13M | -24.6% |
| FY2019 | Dec 31, 2019 | $8.13M | +19.2% |
| FY2018 | Dec 31, 2018 | $6.82M | +237.1% |
| FY2017 | Dec 31, 2017 | $2.02M | -36.6% |
| FY2016 | Dec 31, 2016 | $3.19M | -90.2% |
| FY2015 | Dec 31, 2015 | $32.64M | +123.9% |
| FY2014 | Dec 31, 2014 | $14.58M | +19.5% |
| FY2013 | Dec 31, 2013 | $12.20M | +65.5% |
| FY2012 | Dec 31, 2012 | $7.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $17.76M | +18.7% |
| Q2 FY2026 | Jun 30, 2026 | $18.23M | -10.1% |
| Q1 FY2026 | Mar 31, 2026 | $17.20M | +27.1% |
| Q4 FY2025 | Dec 31, 2025 | $17.49M | -2.4% |
| Q3 FY2025 | Sep 30, 2025 | $14.97M | -9.4% |
| Q2 FY2025 | Jun 30, 2025 | $20.28M | +100.6% |
| Q1 FY2025 | Mar 31, 2025 | $13.53M | +82.6% |
| Q4 FY2024 | Dec 31, 2024 | $17.93M | +153.7% |
| Q3 FY2024 | Sep 30, 2024 | $16.52M | +108.3% |
| Q2 FY2024 | Jun 30, 2024 | $10.11M | +40.3% |
| Q1 FY2024 | Mar 31, 2024 | $7.41M | -8.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.07M | -2.5% |
| Q3 FY2023 | Sep 30, 2023 | $7.93M | +6.4% |
| Q2 FY2023 | Jun 30, 2023 | $7.20M | +25.4% |
| Q1 FY2023 | Mar 31, 2023 | $8.11M | +22.3% |
| Q4 FY2022 | Dec 31, 2022 | $7.25M | +17.3% |
| Q3 FY2022 | Sep 30, 2022 | $7.45M | -2.7% |
| Q2 FY2022 | Jun 30, 2022 | $5.74M | +35.4% |
| Q1 FY2022 | Mar 31, 2022 | $6.64M | +17.4% |
| Q4 FY2021 | Dec 31, 2021 | $6.18M | +103.6% |
| Q3 FY2021 | Sep 30, 2021 | $7.66M | +1145.2% |
| Q2 FY2021 | Jun 30, 2021 | $4.24M | +409.9% |
| Q1 FY2021 | Mar 31, 2021 | $5.65M | +243.0% |
| Q4 FY2020 | Dec 31, 2020 | $3.04M | +127.8% |
| Q3 FY2020 | Sep 30, 2020 | $615.00K | -59.2% |
| Q2 FY2020 | Jun 30, 2020 | $832.00K | -63.8% |
| Q1 FY2020 | Mar 31, 2020 | $1.65M | -44.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.33M | -51.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.51M | -8.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.30M | +72.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.99M | +172.5% |
| Q4 FY2018 | Dec 31, 2018 | $2.74M | +455.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.65M | +219.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.33M | +149.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.10M | +129.0% |
| Q4 FY2017 | Dec 31, 2017 | $493.00K | -42.4% |
| Q3 FY2017 | Sep 30, 2017 | $517.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $533.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $479.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $856.00K | – |
See a number that looks wrong?